The FDA Approves Epsolay Cream For Rosacea Treatment - SPA+CLINIC
Epsolay cream, approved by the FDA, offers a new treatment for rosacea with a 5% benzoyl peroxide formula. It showed a 70% reduction in lesions in trials, with nearly half of participants achieving clear or almost clear skin. Galderma plans to commercialize it in the US, while its availability in Australia remains uncertain.
Reference News
Epsolay cream, approved by the FDA, offers a new treatment for rosacea with a 5% benzoyl peroxide formula. It showed a 70% reduction in lesions in trials, with nearly half of participants achieving clear or almost clear skin. Galderma plans to commercialize it in the US, while its availability in Australia remains uncertain.
Sol-Gel Technologies and Galderma's 5% encapsulated benzoyl peroxide cream, Epsolay, approved for treating rosacea's inflammatory lesions, shows significant efficacy in trials, reducing lesions by nearly 70% and achieving high patient satisfaction. Galderma holds exclusive U.S. commercialization rights.
FDA approved Epsolay, a 5% benzoyl peroxide cream, for treating rosacea's inflammatory lesions in adults. Supported by phase 3 trials, Epsolay showed significant lesion reduction and was well-tolerated, marking a treatment advancement for rosacea sufferers.